Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.54 |
| ▸ | HCK | P08631 | 4/20 | 0.54 |
| ▸ | JAK3 | P52333 | 8/20 | 0.46 |
| ▸ | ITK | Q08881 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21777159 | 1.00 | BTK (0.54) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL30167089 | 1.00 | BTK (0.54) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL23608029 | 1.00 | BTK (0.54) | BTKHCKJAK3ITKEGFR | |
| Hydrochloric Acid SCHEMBL23608055 | 0.99 | BTK (0.54) | BTKHCKJAK3ITKEGFR | |
| Hydrochloric Acid SCHEMBL23607999 | 0.99 | BTK (0.54) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL21777111 | 0.95 | BTK (0.59) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL21777112 | 0.95 | BTK (0.59) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL21777118 | 0.95 | BTK (0.59) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL23608053 | 0.92 | BTK (0.47) | BTKHCKJAK3ITKEGFR | |
| SCHEMBL23608052 | 0.92 | BTK (0.47) | BTKHCKJAK3ITKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227498-B2 | Heterocyclic amine derivative and pharmaceutical composition comprising same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-02-18 | — | — | US | claimed |
| CN-112638910-B | New heterocyclic amine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-06-11 | — | — | CN | claimed |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-03-03 | — | — | US | claimed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | claimed |
| CN-112638910-A | Novel heterocyclic amine derivatives and pharmaceutical compositions comprising the same | 株式会社大熊制药 | 2021-04-09 | — | — | CN | claimed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | claimed |
| EP-4643954-A2 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-12227498-B2 | Heterocyclic amine derivative and pharmaceutical composition comprising same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-02-18 | — | — | US | disclosed |
| CN-115151537-B | Process for preparing heterocyclic amine derivatives | 株式会社大熊制药 | 2024-09-06 | — | — | CN | disclosed |
| CN-112638910-B | New heterocyclic amine derivatives and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-06-11 | — | — | CN | disclosed |
| US-20230094404-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| US-20230094404-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-30 | — | — | US | disclosed |
| EP-4112617-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd. (KR) | 2023-01-04 | — | — | EP | disclosed |
| CN-115151537-A | Process for preparing heterocyclic amine derivatives | 株式会社大熊制药 | 2022-10-04 | — | — | CN | disclosed |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2022-03-03 | — | — | US | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845530-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2021-07-07 | — | — | EP | disclosed |
| CN-112638910-A | Novel heterocyclic amine derivatives and pharmaceutical compositions comprising the same | 株式会社大熊制药 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
| WO-2020045941-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 대웅제약 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094404-A1 | METHOD FOR PREPARATION OF HETEROCYCLICAMINE DERIVATIVES | HNMT, MAOB, PNMT | BTK 3135/4885HCK 1397/4885JAK3 1540/4885 |
| US-20220064155-A1 | NOVEL HETEROCYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | H1-5, H1-2, SSB | BTK 133/4885HCK 3523/4885JAK3 224/4885 |
| US-12227498-B2 | Heterocyclic amine derivative and pharmaceutical composition comprising same | H1-5, SSB, H1-2 | BTK 144/4885HCK 3206/4885JAK3 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.